Risperidone

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but with stricter controls. Biosimilars, including Humira’s, have struggled with adoption despite cost savings potential. Optum Rx also adds and removes various oncology and CNS medications for 2025.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but is subject to prior authorization. Biosimilars have struggled with low adoption despite cost advantages, but large PBMs like CVS Health are shifting towards biosimilars. Optum Rx also adds and removes various oncology and CNS medications from its 2025 formulary.

Intra-Cellular Therapies seeks FDA approval for Caplyta as an adjunct treatment for major depressive disorder (MDD), potentially expanding its market to over $1 billion. Caplyta, already approved for schizophrenia and bipolar disorder, saw Q3 sales of $175 million, with Q4 projections at least $193 million. The MDD submission is based on Phase III trials showing symptom improvement when paired with an antidepressant. Jefferies estimates a 90–95% approval likelihood, predicting a company valuation of $9–12 billion. Intra-Cellular is also exploring Caplyta for autism and developing ITI-214 for Parkinson’s and ITI-333 for opioid use.

Risperidone, a second-generation antipsychotic, treats schizophrenia, bipolar disorder, and autism-related hyperactivity. It inhibits D2 dopamine and 5-HT2A serotonin receptors, reducing psychotic symptoms. Risperidone nano/microcarriers enhance bioavailability, reduce side effects, and improve patient compliance. Formulation strategies include liposomes, nanoparticles, nanoemulsions, and niosomes, aiming to improve solubility, stability, and targeted delivery. Toxicological studies highlight neurological and immunosuppressive side effects. Clinical trials show efficacy in psychosis management, and patents focus on innovative formulations. Future research aims to optimize nano/microcarrier systems for better drug delivery.

Teva Pharmaceutical Industries Limited's TEVA stock declined 10% despite strong Q3 results, driven by underwhelming guidance. The company's branded drugs Austedo and Ajovy are key growth drivers, with expected sales of $1.6 billion and $500 million in 2024, respectively. Teva's generics and biosimilars pipeline is robust, with several launches expected by 2027. The company resolved opioid litigation for $4.25 billion, and its stock valuation is attractive, making it a potential buying opportunity for long-term investors.

Teva's Phase III SOLARIS trial of TEV-'749 in schizophrenia patients showed significant improvements in social functioning and quality of life. The subcutaneous long-acting injectable met primary endpoint in PANSS total score, with no PDSS observed.

Teva Pharmaceuticals announces positive Phase 3 SOLARIS trial results for TEV-‘749, a once-monthly subcutaneous olanzapine formulation for schizophrenia, showing significant improvements in social functioning and quality of life with a safe profile.

Teva presented positive Phase 3 SOLARIS trial results for Olanzapine LAI, showing significant improvements in social functioning and quality of life in schizophrenia patients, with no PDSS events. Real-world data on UZEDY revealed high adherence rates among socially vulnerable schizophrenia patients.

Teva presents positive data on TEV-'749's social functioning and quality of life improvements in schizophrenia patients at Psych Congress 2024, with no PDSS events reported. Real-world analyses of UZEDY show high adherence rates in adults with treatment barriers.